

# SBIO

## ALPS Medical Breakthroughs ETF

### Analyst Report

SBIO tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials.

### ESG Themes and Scores

4.45/10

ESG Rate

13.86%

Global Percentile

5.86%

Peer Percentile

### Performance Data

	SBIO	ETF Database Category Average	Factset Segment Average
1 Month	-1.32%	5.38%	1.51%
3 Month	-11.54%	0.10%	-6.23%
YTD Return	0.73%	6.61%	2.20%
1 Year Return	3.78%	7.06%	-1.30%
3 Year Return	1.33%	0.54%	4.98%
5 Year Return	-3.13%	2.37%	2.70%

### Top 5 Holdings

Symbol	Holding	% Assets
AXSM	Axsome Therapeutics, Inc.	4.10%
ALKS	Alkermes Public Limited Company	4.02%
VRNA	Verona Pharma plc Sponsored ADR	3.64%
RNA	Avidity Biosciences Inc	3.03%
AKRO	Akero Therapeutics, Inc.	3.01%

### Vitals

Issuer	SS&C
Brand	ALPS
Structure	ETF
Expense Ratio	0.50%
Inception	Dec 31, 2014
Index Tracked	S-Network Medical Breakthroughs Index

### ETF Database Themes

Category	Health & Biotech Equities
Asset Class	Equity
Asset Class Size	Small-Cap
Asset Class Style	Growth
Region (General)	North America
Region (Specific)	U.S.

### FactSet Classifications

Segment	Equity: U.S. Biotechnology
Category	Sector
Focus	Health Care
Niche	Biotechnology
Strategy	Fundamental
Weighting	Market Cap

